KALA BIO, Inc.
KALAHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeKALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United. With a market capitalization of $13.6M, it sits in micro-cap territory. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Market Cap
$13.6M
Beta
-2.36
P/E (TTM)
—
P/E (Fwd)
-0.11
EPS (TTM)
$-102.17
EPS (Fwd)
$-6.67
ROE
-238.7%
ROA
-69.3%
Cash
$8.8M
Total Debt
$0
Free CF
-$20.6M
52W Change
-99.7%
Annual Financials
Cash vs Debt
Where KALA stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, KALA finished 93.43% below its 150-day moving average ($14.61) and 97.05% below its 200-day moving average ($32.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KALA overbought or oversold?
At the July 15, 2026 close, KALA's RSI(14) was 2.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
KALA BIO, Inc. reports $8.8M in cash and $0 in total debt. Free cash flow is running at -$20.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -238.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $3.9M (2022) to $0 (2025), a 100% decline worth watching.
KALA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for KALA BIO, Inc. and its sector.